R&D Pipeline
Innovation R&D Pipeline
Potential of our proprietary technology platform to be expanded into more research and therapeutic areas in the near future.
Therapeutic Area Program Target Modality Indication Discovery Preclinical Phase l Phase ll
Oncology
ALK201 FGFR2b ADC GC, NSCLC & Solid Tumors
ALK202 EGFR/cMET Bispecific ADC NSCLC, CRC & Solid Tumors
ALK101 EGFR/cMET Bispecific Antibody NSCLC, CRC & Solid Tumors
ALKN205 Undisclosed ADC Solid Tumors
ALKN206 Undisclosed ADC Solid Tumors
Immunology
ALKN401 Undisclosed Bispecific Antibody IgG Associated Diseases
Leveraging our powerful technology platform to drive continuous expansion of innovative pipeline